{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:13:39Z","timestamp":1753877619892,"version":"3.41.2"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"vor","delay-in-days":308,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background. \u2003Hepatitis C virus (HCV) treatment access among human immunodeficiency virus (HIV)\/HCV-coinfected people who inject drugs is poor, despite a high burden of disease in this population. Understanding barriers and facilitators to HCV treatment uptake is critical to the implementation of new direct-acting antivirals.<\/jats:p>\n               <jats:p>Methods. \u2003We conducted in-depth interviews with patients, physicians, and social workers at an HIV treatment facility and methadone maintenance treatment centers in Guangzhou, China to identify barriers and facilitators to HCV treatment. We included patients who were in various stages of HCV treatment and those who were not treated. We used standard qualitative methods and organized data into themes.<\/jats:p>\n               <jats:p>Results. \u2003Interview data from 29 patients, 8 physicians, and 3 social workers were analyzed. Facilitators and barriers were organized according to a modified Consolidated Framework for Implementation Research schematic. Facilitators included patient trust in physicians, hope for a cure, peer networks, and social support. Barriers included ongoing drug use, low HCV disease knowledge, fragmented reimbursement systems, HIV exceptionalism, and stigma.<\/jats:p>\n               <jats:p>Conclusions. \u2003Expanding existing harm reduction programs, HIV treatment programs, and social services may facilitate scale-up of direct-acting antivirals globally. Improving integration of ancillary social and mental health services within existing HIV care systems may facilitate HCV treatment access.<\/jats:p>","DOI":"10.1093\/ofid\/ofw065","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T04:48:28Z","timestamp":1466916508000},"source":"Crossref","is-referenced-by-count":8,"title":["Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion"],"prefix":"10.1093","volume":"3","author":[{"given":"Carissa E.","family":"Chu","sequence":"first","affiliation":[{"name":"School of Medicine, University of California San Francisco"},{"name":"UNC-Project China, Guangzhou"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Sociology and Anthropology, Sun Yat-sen University, Guangzhou"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"He","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People's Hospital, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kali","family":"Zhou","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People's Hospital, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Sociology and Anthropology, Sun Yat-sen University, Guangzhou"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Cai","sequence":"additional","affiliation":[{"name":"Guangzhou Eighth People's Hospital, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvin","family":"Geng","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Volberding","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph D.","family":"Tucker","sequence":"additional","affiliation":[{"name":"UNC-Project China, Guangzhou"},{"name":"School of Sociology and Anthropology, Sun Yat-sen University, Guangzhou"},{"name":"Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,6,24]]},"reference":[{"key":"2020081005370235600_OFW065C1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of HCV infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"article-title":"Hepatitis C.","year":"2014","author":"World Health Organization","key":"2020081005370235600_OFW065C2"},{"key":"2020081005370235600_OFW065C3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"2020081005370235600_OFW065C4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"2020081005370235600_OFW065C5","doi-asserted-by":"crossref","first-page":"g3308","DOI":"10.1136\/bmj.g3308","article-title":"Antiviral treatment of hepatitis C","volume":"348","author":"Feeney","year":"2014","journal-title":"BMJ"},{"key":"2020081005370235600_OFW065C6","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"2020081005370235600_OFW065C7","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1053\/j.gastro.2012.02.012","article-title":"Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals","volume":"142","author":"Naggie","year":"2012","journal-title":"Gastroenterology"},{"key":"2020081005370235600_OFW065C8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.antiviral.2012.10.011","article-title":"The changing face of hepatitis C in the new era of direct-acting antivirals","volume":"97","author":"Soriano","year":"2013","journal-title":"Antiviral Research"},{"article-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection","year":"2014","author":"World Health Organization","key":"2020081005370235600_OFW065C9"},{"key":"2020081005370235600_OFW065C10","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"},{"key":"2020081005370235600_OFW065C11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1473-3099(14)70946-6","article-title":"HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010\u201312: a retrospective observational cohort study","volume":"14","author":"Zhang","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2020081005370235600_OFW065C12","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/liv.12565","article-title":"Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review","volume":"34","author":"Papatheodoridis","year":"2014","journal-title":"Liver Int"},{"key":"2020081005370235600_OFW065C13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-6405-11-16","article-title":"German cohort of HCV mono-infected and HCV\/HIV co-infected patients reveals relative under-treatment of co-infected patients","volume":"11","author":"Beisel","year":"2014","journal-title":"AIDS Res Ther"},{"key":"2020081005370235600_OFW065C14","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","article-title":"Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic","volume":"20","author":"Mehta","year":"2006","journal-title":"AIDS"},{"key":"2020081005370235600_OFW065C15","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/cid\/cit263","article-title":"Understanding barriers to hepatitis C virus care and stigmatization from a social perspective","volume":"57","author":"Treloar","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020081005370235600_OFW065C16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1089\/apc.2010.0142","article-title":"Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration","volume":"24","author":"Swan","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"2020081005370235600_OFW065C17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1365-2893.2009.01250.x","article-title":"Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.","volume":"17","author":"Treloar","year":"2010","journal-title":"J Viral Hepat"},{"key":"2020081005370235600_OFW065C18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.socscimed.2013.01.031","article-title":"Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting","volume":"83","author":"Harris","year":"2013","journal-title":"Soc Sci Med"},{"key":"2020081005370235600_OFW065C19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/009145091003700403","article-title":"Notions of injecting drug users' candidacy for hepatitis C treatment: conflicting provider, patient, and public health perspectives","volume":"37","author":"Coupland","year":"2010","journal-title":"Contemp Drug Probl"},{"key":"2020081005370235600_OFW065C20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"2020081005370235600_OFW065C21","doi-asserted-by":"crossref","first-page":"e76931","DOI":"10.1371\/journal.pone.0076931","article-title":"High prevalence of HIV, HCV and tuberculosis and associated risk behaviours among new entrants of methadone maintenance treatment clinics in Guangdong Province, China","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"volume-title":"The Discovery of Grounded Theory: Strategies for Qualitative Research.","year":"2009","author":"Glaser","key":"2020081005370235600_OFW065C22"},{"volume-title":"Discourse and Social Psychology: Beyond Attitudes and Behaviour","year":"1987","author":"Potter","key":"2020081005370235600_OFW065C23"},{"key":"2020081005370235600_OFW065C24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implement Sci"},{"key":"2020081005370235600_OFW065C25","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/cis367","article-title":"HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms","volume":"55","author":"Taylor","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020081005370235600_OFW065C26","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJM199105233242111","article-title":"Public health policy and the AIDS epidemic: an end to HIV exceptionalism?","volume":"324","author":"Bayer","year":"1991","journal-title":"N Engl J Med"},{"key":"2020081005370235600_OFW065C27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/1472-6963-14-308","article-title":"A cross-sectional study describing factors associated with utilisation of GP services by a cohort of people who inject drugs","volume":"14","author":"Nambiar","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"2020081005370235600_OFW065C28","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/cid\/cit271","article-title":"Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all","volume":"57","author":"Bruggmann","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020081005370235600_OFW065C29","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/cid\/cit305","article-title":"Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study","volume":"57","author":"Alavi","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020081005370235600_OFW065C30","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1093\/cid\/cit265","article-title":"Enhancing assessment and treatment of hepatitis C in the custodial setting","volume":"57","author":"Post","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020081005370235600_OFW065C31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amepre.2005.03.010","article-title":"Integrating hepatitis, STD, and HIV services into a drug rehabilitation program","volume":"29","author":"Gunn","year":"2005","journal-title":"Am J Prev Med"},{"key":"2020081005370235600_OFW065C32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.drugpo.2007.03.001","article-title":"Integration and co-location of HIV\/AIDS, tuberculosis and drug treatment services","volume":"18","author":"Sylla","year":"2007","journal-title":"Int J Drug Policy"},{"key":"2020081005370235600_OFW065C33","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/cid\/cis227","article-title":"Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV\/AIDS","volume":"54","author":"Ford","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020081005370235600_OFW065C34","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJMp1407373","article-title":"Public trust in physicians\u2014U.S. medicine in international perspective","volume":"371","author":"Blendon","year":"2014","journal-title":"N Engl J Med"},{"article-title":"Gilead's License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: A Fool's Bargain - Myths and Facts","year":"2014","author":"Forette","key":"2020081005370235600_OFW065C35"},{"author":"Gilead","key":"2020081005370235600_OFW065C36","article-title":"Chronic Hepatitis C Treatment Expansion: Generic Manufacturing for Developing Countries"},{"key":"2020081005370235600_OFW065C37","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJMp1400160","article-title":"Treating hepatitis C in lower-Income countries","volume":"370","author":"Jayasekera","year":"2014","journal-title":"N Engl J Med"},{"key":"2020081005370235600_OFW065C38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/aid.2014.0200","article-title":"Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China","volume":"31","author":"Chu","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081005370235600_OFW065C39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/jgh.12355","article-title":"Targeted hepatitis C screening among ex-injection drug users in the community","volume":"29","author":"Wong","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"2020081005370235600_OFW065C40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1300\/J013v39n04_07","article-title":"\u201cEyes Wide Shut\u201d: narratives of women living with hepatitis C in Australia","volume":"39","author":"Crockett","year":"2004","journal-title":"Women Health"},{"year":"2015","key":"2020081005370235600_OFW065C41","article-title":"Strategies to Secure Access to Generic Hepatitis C Medicines."}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/3\/2\/ofw065\/33604358\/ofw065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/3\/2\/ofw065\/33604358\/ofw065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T09:38:18Z","timestamp":1597052298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofw065\/2399327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofw065","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2016]]},"published":{"date-parts":[[2016]]},"article-number":"ofw065"}}